Status:
RECRUITING
Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor
Lead Sponsor:
Adelphi Real World
Conditions:
Axial Spondylarthritis (axSpA)
Psoriatic Arthritis (PsA)
Eligibility:
All Genders
18+ years
Brief Summary
This observational study will target patients with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) who have started treatment with bimekizumab, upadacitinib, risankizumab, guselkumab, or...
Detailed Description
Patient experience surveys will be administered prospectively throughout the study period, whereas the review of patients' medical records will be conducted retrospectively towards the end of the stud...
Eligibility Criteria
Inclusion
- Participant has a clinical diagnosis of axial spondyloarthritis (axSpA) or psoriatic arthritis (PsA).
- Participant has been prescribed advanced therapy within one month prior to enrolment in the study, to treat their axSpA or PsA.
- Participant is aged 18 years or older at enrolment.
Exclusion
- Participation in a clinical trial at enrolment.
Key Trial Info
Start Date :
July 7 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2027
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT07166315
Start Date
July 7 2025
End Date
March 1 2027
Last Update
September 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Royal National Hospital for Rheumatic Diseases
Bath, Somerset, United Kingdom, BA1 3NG